Objective
We evaluated the biological effects of low-dose methotrexate (LDMTX) on 3 novel brachial artery grayscale ultrasound measures that may indicate subclinical arterial injury.
Approach and Results
Exploratory analysis from a clinical trial of people with HIV infection at increased cardiovascular disease risk who were randomly assigned to LDMTX (target dose 15 mg/week) or placebo. Brachial artery ultrasound grayscale median, gray level difference statistic texture contrast (GLDS-CON), and gray level texture entropy were measured at baseline and after 24 weeks of intervention. Findings from the intention-to-treat (N=148) and adequately dosed (N=118) populations were consistent, so the adequately dosed population results are presented. Participants were a median (Q1, Q3) age of 54 (50, 60) years. After 24 weeks, the LDMTX intervention was associated with a 25.4% (−18.1, 58.6; p=0.007) increase in GLDS-CON compared to 1.3% (−29.1, 44.7; p=0.97) with placebo (p=0.05) and a 0.10 u (−0.06, 0.23; p=0.026) increase in entropy compared to 0.02 u (−0.11, 0.14; p=0.54) with placebo (p=0.14). At week 24, changes in CD4+ T-cells correlated inversely with changes in GLDS-CON (ρ= −0.20, p=0.031), and entropy (ρ= −0.21, p=0.023). Changes in D-dimer levels, but no other inflammatory biomarkers, also correlated inversely with changes in GLDS-CON (ρ= −0.23, p=0.014) and entropy (ρ= −0.26, p=0.005).
Conclusions
Brachial artery GLDS-CON and entropy increased after 24 weeks of LDMTX, though the latter was not significantly different from placebo. Grayscale changes were associated with decreases in CD4+ T-cell and D-dimer concentrations and may indicate favorable arterial structure changes.